BIIB Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 2332 min ago

@ $208.76

Ausgestellt: 26 Apr 2024 @ 21:56

Rendite: 0.07%

Vorheriges Signal: Apr 26 - 16:13

Vorheriges Signal: Verkaufen

Rendite: 1.91 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:00):
Our systems believe the stock currently is undervalued by 0.28% compare to its pairs and should correct upwards.

Stats
Tagesvolumen	1.89M
Durchschnittsvolumen	1.27M
Marktkapitalisierung	30.42B
EPS	$0 ( 2024-04-24 )
Nächstes Ertragsdatum	( $3.96 ) 2024-07-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	26.11
ATR14	$11.62 (5.56%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Singhal Priya	Sell	93	Common Stock
2024-04-01	Murphy Nicole	Buy	240	Common Stock
2024-04-01	Murphy Nicole	Sell	117	Common Stock
2024-04-01	Murphy Nicole	Sell	240	Restricted Stock Unit
2024-02-22	Singhal Priya	Sell	262	Common Stock

INSIDER POWER
4.52
Last 100 transactions
Buy: 80 749 \| Sell: 73 436

Korrelation (AI algo v.1.1b): Undervalued: 0.28% $209.47 paired level. (Der Algorithmus verfolgt in Echtzeit die Änderungen der am stärksten korrelierten Aktien und gibt eine sofortige Aktualisierung)

Volumen Korrelation

Lang: 0.15 (neutral)

Kurz: -0.40 (neutral)

Signal:(35) Neutral

Biogen Inc Korrelation

10 Am meisten positiv korreliert
EVCM	0.883
RBNC	0.879
NLTX	0.879
ACLX	0.878
EGRX	0.873
ARCT	0.865
HBIO	0.863
NATI	0.862
FCFS	0.861
MDLZ	0.858

10 Am meisten negativ korreliert
NYMTN	-0.908
WTRE	-0.908
RNMC	-0.903
REIT	-0.903
KBWD	-0.9
SDVY	-0.899
NEOG	-0.899
FFBW	-0.898
XT	-0.895
ICHR	-0.895

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Biogen Inc Korrelation - Währung/Rohstoff

-0.63
( weak negative )

-0.49
( neutral )

0.00
( neutral )

-0.25
( neutral )

-0.08
( neutral )

0.48
( neutral )

Biogen Inc Finanzdaten

Annual	2023
Umsatz:	$9.84B
Bruttogewinn:	$7.30B (74.24 %)
EPS:	$8.02

FY	2023
Umsatz:	$9.84B
Bruttogewinn:	$7.30B (74.24 %)
EPS:	$8.02

FY	2022
Umsatz:	$10.17B
Bruttogewinn:	$7.90B (77.61 %)
EPS:	$20.97

FY	2021
Umsatz:	$10.98B
Bruttogewinn:	$8.87B (80.79 %)
EPS:	$10.44

Financial Reports:

No articles found.

Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.